APR 22, 2015 7:54 AM PDT

Genetic Variance Explains Poor Response to Asthma Medications

WRITTEN BY: Ilene Schneider
Researchers have identified a biological basis for asthmatic children who do not respond well to corticosteroid treatment - currently the most effective treatment for chronic asthma and acute asthma attack.
Effective treatment is either absent or incomplete in 40-70 percent of childhood asthma cases, researchers say.
Conducted at Cincinnati Children's Hospital Medical Center, the study also identifies a genetic pathway that could open the possibility of new therapies for difficult-to-treat patients. The findings are reported April 21 in The Journal of Allergy and Clinical Immunology, published by the American Academy of Allergy Asthma and Immunology.

The researchers performed genome-wide analysis of nasal epithelial cells collected from children experiencing acute asthma exacerbation. They compared genetic expression and medical responses in children who responded well to corticosteroids therapy to those who did not.

"Genome-wide analysis allowed us to identify a gene, VNN-1, whose expression discriminated between good and poor responders to systemic corticosteroid treatment," said Gurjit Khurana Hershey, MD, PhD, senior author and director of Asthma Research at Cincinnati Children's. "This may serve as a clinically useful biomarker to identify a subset of difficult-to-treat asthmatic children, and targeting the VNN-1 pathway may be useful as a therapeutic strategy."

Asthma affects close to 26 million people in the United States, 7 million of them children. Although people suffering from asthma share similar clinical symptoms, it is triggered by multiple genetic and environmental factors. This makes asthma a series of respiratory syndromes that can be difficult to study and treat and personalized therapeutic management is needed to achieve the best outcomes, according to the researchers.

Less-than-optimal management of childhood asthma is highlighted by the fact that nearly two-thirds of asthmatic children report at least one attack a year. And researchers estimate that effective treatment is either absent or incomplete in 40-70 percent of cases, highlighting the need for new treatment strategies. This includes the subset of children who do not respond well to systemic corticosteroid therapy.

"Difficult-to-treat patients account for over 50 percent of health care costs associated with asthma," Hershey said. "There are new drugs that may be helpful, as well as those that affect the VNN-1 pathway, but they have not been tested in asthma. This study provides the basis for a biomarker to determine which patients might be best to target with new treatments."

The study included 57 children between ages 5 and 18 who were admitted through the Emergency Department at Cincinnati Children's and hospitalized for treatment of their asthma. In an initial group of patients experiencing asthma attack, nasal epithelia cells were collected and tested for comparative VNN-1 expression. Researchers then tested a second group of patients to verify results of the first group.

Starting with a candidate list of 20,000 genes, researchers screened down to eight before singling out VNN-1 as the primary target. They conducted a series of cell biology tests in the lab to show that VNN-1 expression is required for inhaled corticoids to work during asthma attack. In cells from patients whose asthma did not respond well to treatment, researchers found a biochemical variation in the VNN-1 molecular network that hindered its expression.

The researchers next tested and confirmed their clinical findings in laboratory mouse models of asthma, and produced data suggesting that targeting the VNN-1 pathway therapeutically might be a way to improve outcomes for difficult-to-treat asthmatic children.

Testing continues in laboratory models to better determine the VNN-1 pathway's role in contributing to airway inflammation and hyper-responsiveness in asthma. Researches are also testing drugs that target the VNN-1 pathway to determine which, if any, might improve treatment for asthmatic children who do not respond to current treatments.

Enhanced expression of VNN-1 is associated with multiple human diseases, such as inflammatory bowel disease, immune thrombocytopenia and system lupus erythematosus. This is the first study to report improperly regulated expression of VNN-1 and its mRNA (which help translate and transmit genetic information) in asthma.

Source: Cincinnati Children's Hospital Medical Center
About the Author
Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 25, 2022
Cell & Molecular Biology
New Imaging Tools Provide Insights Into Cell Stress
SEP 25, 2022
New Imaging Tools Provide Insights Into Cell Stress
In cells, active genes are transcribed into mRNA molecules, which can be edited and processed in a variety of ways, to u ...
OCT 07, 2022
Earth & The Environment
United Nations Genetic Diversity Target Deadline Has Passed
OCT 07, 2022
United Nations Genetic Diversity Target Deadline Has Passed
In a recent study published in Science, an international team of researchers led by Stanford University examine how habi ...
OCT 08, 2022
Coronavirus
Carriers of Certain APOE Variants are More Vulnerable to Severe COVID-19
OCT 08, 2022
Carriers of Certain APOE Variants are More Vulnerable to Severe COVID-19
Researchers have long known that certain things are risk factors for severe cases of COVID-19, such as old age or obesit ...
OCT 17, 2022
Genetics & Genomics
Genetic Markers Can Differentiate Between ADHD & Autism
OCT 17, 2022
Genetic Markers Can Differentiate Between ADHD & Autism
The symptoms of attention deficit/hyperactivity disorder (ADHD) and autism have many things in common; they are both com ...
NOV 04, 2022
Immunology
From Fleas to Natural Selection: The Black Plague & Modern Immunology
NOV 04, 2022
From Fleas to Natural Selection: The Black Plague & Modern Immunology
Acknowledgments of our many physiological changes since the evolution of modern humans have been studied profusely, espe ...
NOV 17, 2022
Neuroscience
Fluorescent Proteins Extend Blood Flow Tracking to Months in Mice
NOV 17, 2022
Fluorescent Proteins Extend Blood Flow Tracking to Months in Mice
Harmless, fluorescent proteins allow scientists to track blood flow in mice. The advance could help researchers monitor ...
Loading Comments...